-
1 Comment
BB Biotech AG is currently in a long term uptrend where the price is trading 11.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Based on the above factors, BB Biotech AG gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | CH0038389992 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Dividend Yield | 6.6% |
|---|---|
| Beta | 0.9 |
| Market Cap | 2B |
| PE Ratio | 11.78 |
| Target Price | 62.5108 |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BBZA.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
